Clinical Trial Update: Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART) [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update evaluating efgartigimod alfa (Vyvgart) to treat bullous diseases by targeting collagen VII antibodies in Epidermolysis Bullosa and relat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dystrophic Epidermolysis Bullosa
• Epidermolysis Bullosa
• Epidermolysis Bullosa Acquisita
• Recessive Dystrophic Epidermolysis Bullosa

Drugs mentioned

• VYVGART (EFGARTIGIMOD ALFA)

Snippet

Sponsor: M. Peter Marinkovich | Conditions: Epidermolysis Bullosa (EB), Epidermolysis Bullosa Acquisita | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING